Talimogene laherparepvec (T-VEC) as cancer immunotherapy. (Q38612926)

scientific article

Language	Label	Description	Also known as
English	Talimogene laherparepvec (T-VEC) as cancer immunotherapy.	scientific article

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed ID

26488034

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26488034%20AND%20SRC:MED&resulttype=core&format=json

retrieved

27 February 2020

title

Talimogene laherparepvec (T-VEC) as cancer immunotherapy (English)

1 reference

stated in

Europe PubMed Central

PubMed ID

26488034

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26488034%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

2

1 reference

stated in

Europe PubMed Central

PubMed ID

26488034

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26488034%20AND%20SRC:MED&resulttype=core&format=json

retrieved

27 February 2020

author name string

F J Kohlhapp

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed ID

26488034

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26488034%20AND%20SRC:MED&resulttype=core&format=json

retrieved

27 February 2020

H L Kaufman

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed ID

26488034

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26488034%20AND%20SRC:MED&resulttype=core&format=json

retrieved

27 February 2020

publication date

1 September 2015

1 reference

stated in

Europe PubMed Central

PubMed ID

26488034

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26488034%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

Europe PubMed Central

PubMed ID

26488034

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26488034%20AND%20SRC:MED&resulttype=core&format=json

retrieved

27 February 2020

volume

51

1 reference

stated in

Europe PubMed Central

PubMed ID

26488034

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26488034%20AND%20SRC:MED&resulttype=core&format=json

retrieved

27 February 2020

issue

9

1 reference

stated in

Europe PubMed Central

PubMed ID

26488034

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26488034%20AND%20SRC:MED&resulttype=core&format=json

retrieved

27 February 2020

page(s)

549-558

1 reference

stated in

Europe PubMed Central

PubMed ID

26488034

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26488034%20AND%20SRC:MED&resulttype=core&format=json

retrieved

27 February 2020

Identifiers

DOI

10.1358/DOT.2015.51.9.2383044

1 reference

stated in

Europe PubMed Central

PubMed ID

26488034

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26488034%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

Europe PubMed Central

PubMed ID

26488034

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26488034%20AND%20SRC:MED&resulttype=core&format=json

Talimogene laherparepvec (T-VEC) as cancer immunotherapy. (Q38612926)

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Navigation menu

Talimogene laherparepvec (T-VEC) as cancer immunotherapy. (Q38612926)

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Navigation menu

Search